Photodynamic dose does not correlate with long-term tumor response to mTHPC-PDT performed at several drug-light intervals

Medical Physics

Volumn 35, Issue 8, 2008, Pages 3518-3526

  Wang, Ken Kang Hsin ^a   Mitra, Soumya ^a   Foster, Thomas H ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Dosimetry; mTHPC; Numerical simulation; Photodynamic therapy

Indexed keywords

COMPUTER SIMULATION; DEPOSITION; DOSIMETRY; IRRADIATION; MAMMALS; OXYGEN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; TUMORS;

BIOLOGICAL RESPONSE; DRUG-LIGHT INTERVALS; HEAD-AND-NECK CANCER; MICROSCOPIC ANALYSIS; MTHPC; PHOTODYNAMIC THERAPY (PDT); PHOTOPHYSICAL PROPERTIES; THEORETICAL MODELING;

DRUG DOSAGE;

SINGLET OXYGEN; TEMOPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSIMETRY; FEMALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

MUS; TETRA;

EID: 48349089129     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.2952360     Document Type: Article

References (36)

1. S. B. Brown, E. A. Brown, and I. Walker, " The present and future role of photodynamic therapy in cancer treatment.," Lancet Oncol. 5, 497-508 (2004).
2. A. K. D'Cruz, M. H. Robinson, and M. A. Biel, " mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study of 128 patients.," Head Neck 26, 232-240 (2004).
3. S. Andrejevic-Blant, C. Hadjur, J. P. Ballini, G. Wagnieres, C. Fontolliet, H. van den Bergh, and P. Monnier, " Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: Optimal drug-light interval.," Br. J. Cancer 76, 1021-1028 (1997).
4. P. Cramers, M. Ruevekamp, H. Oppelaar, O. Dalesio, P. Baas, and F. A. Stewart, " Foscan uptake and tissue distribution in relation to photodynamic efficacy.," Br. J. Cancer 88, 283-290 (2003).
5. M. Triesscheijn, M. Ruevekamp, M. Aalders, P. Baas, and F. A. Stewart, " Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response.," Photochem. Photobiol. 81, 1161-1167 (2005).
6. S. Mitra, E. Maugain, L. Bolotine, F. Guillemin, and T. H. Foster, " Temporally and spatially heterogeneous distribution of mTHPC in a murine tumor observed by two-color confocal fluorescence imaging and spectroscopy in a whole-mount model.," Photochem. Photobiol. 81, 1123-1130 (2005).
7. S. Mitra and T. H. Foster, " Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin.," Photochem. Photobiol. 81, 849-859 (2005).
8. K. K. Wang, S. Mitra, and T. H. Foster, " A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy.," Med. Phys. 34, 282-293 (2007).
9. S. Coutier, S. Mitra, L. N. Bezdetnaya, R. M. Parache, I. Georgakoudi, T. H. Foster, and F. Guillemin, " Effects of fluence rate on cell survival and photobleaching in meta-tetra-(hydroxyphenyl)chlorin-photosensitized colo 26 multicell tumor spheroids.," Photochem. Photobiol. 73, 297-303 (2001).
10. J. A. Hudson and D. B. Cater, " An analysis of factors affecting tissue oxygen tension.," Proc. R. Soc. London, Ser. B 161, 247-274 (1964).
11. I. Georgakoudi, M. G. Nichols, and T. H. Foster, " The mechanism of photofrin® photobleaching and its consequences for photodynamic dosimetry.," Photochem. Photobiol. 65, 135-144 (1997).
12. J. C. Finlay, " Reflectance and fluorescence spectroscopies in photodynamic therapy.," Ph.D. thesis, University of Rochester, 2003, http://hdl.handle.net/1802/2805.
13. J. S. Dysart, G. Singh, and M. S. Patterson, " Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells.," Photochem. Photobiol. 81, 196-205 (2005).
14. J. C. Finlay, S. Mitra, and T. H. Foster, " In vivo mTHPC photobleaching in normal rat skin exhibits unique irradiance-dependent features.," Photochem. Photobiol. 75, 282-288 (2002).
15. J. S. Dysart, M. S. Patterson, T. J. Farrell, and G. Singh, " Relationship between mTHPC fluorescence photobleaching and cell viability during in vitro photodynamic treatment of DP16 cells.," Photochem. Photobiol. 75, 289-295 (2002).
16. H. J. Jones, D. I. Vernon, and S. B. Brown, " Photodynamic therapy effect of m-THPC (Foscan) in vivo: Correlation with pharmacokinetics.," Br. J. Cancer 89, 398-404 (2003).
17. S. Mitra and T. H. Foster, " In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6 (NPe6).," Neoplasia 10, 429-438 (2008).
18. C. E. Bigelow, D. L. Conover, and T. H. Foster, " Confocal fluorescence spectroscopy and anisotropy imaging system.," Opt. Lett. 28, 695-697 (2003).
19. W. J. Cottrell, A. R. Oseroff, and T. H. Foster, " A portable instrument that integrates irradiation with fluorescence and reflectance spectroscopies during clinical photodynamic therapy of cutaneous disease.," Rev. Sci. Instrum. 77, 064302 (2006).
20. D. J. Robinson, H. S. de Bruijn, N. van der Veen, M. R. Stringer, S. B. Brown, and W. M. Star, " Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin.," Photochem. Photobiol. 69, 61-70 (1999).
21. M. T. Jarvi, M. J. Niedre, M. S. Patterson, and B. C. Wilson, " Singlet oxygen luminescence dosimetry (SOLD) for photodynamic therapy: Current status, challenges and future prospects.," Photochem. Photobiol. 82, 1198-1210 (2006).
22. B. W. Henderson, S. M. Waldow, T. S. Mang, W. R. Potter, P. B. Malone, and T. J. Dougherty, " Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.," Cancer Res. 45, 572-576 (1985).
23. W. J. de Vree, M. C. Essers, H. S. de Bruijn, W. M. Star, J. F. Koster, and W. Sluiter, " Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo.," Cancer Res. 56, 2908-2911 (1996).
24. J. Sun, I. Cecic, C. S. Parkins, and M. Korbelik, " Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours.," Photochem. Photobiol. Sci. 1, 690-695 (2002).
25. S. O. Gollnick, B. Owczarczak, and P. Maier, " Photodynamic therapy and anti-tumor immunity.," Lasers Surg. Med. 38, 509-515 (2006).
26. N. L. Oleinick and H. H. Evans, " The photobiology of photodynamic therapy: Cellular targets and mechanisms.," Radiat. Res. 150, S146-S156 (1998).
27. J. J. Reiners, Jr., J. A. Caruso, P. Mathieu, B. Chelladurai, X. M. Yin, and D. Kessel, " Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage.," Cell Death Differ 9, 934-944 (2002).
28. M. C. Luna, A. Ferrario, S. Wong, A. M. Fisher, and C. J. Gomer, " Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter.," Cancer Res. 60, 1637-1644 (2000).
29. S. Mitra, E. M. Goren, J. G. Frelinger, and T. H. Foster, " Activation of heat shock protein 70 promoter with meso-tetrahydroxyphenyl chlorin photodynamic therapy reported by green fluorescent protein in vitro and in vivo.," Photochem. Photobiol. 78, 615-622 (2003).
30. S. Gross, A. Gilead, A. Scherz, M. Neeman, and Y. Salomon, " Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI.," Nat. Med. 9, 1327-1331 (2003).
31. J. C. Finlay and T. H. Foster, " Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady-state diffuse reflectance at a single, short source-detector separation.," Med. Phys. 31, 1949-1959 (2004).
32. A. A. Stratonnikov and V. B. Loschenov, " Evaluation of blood oxygen saturation in vivo from diffuse reflectance spectra.," J. Biomed. Opt. 6, 457-467 (2001).
33. G. Yu, T. Durduran, C. Zhou, H. W. Wang, M. E. Putt, H. M. Saunders, C. M. Sehgal, E. Glatstein, A. G. Yodh, and T. M. Busch, " Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy.," Clin. Cancer Res. 11, 3543-3552 (2005).
34. B. Chen, B. W. Pogue, I. A. Goodwin, J. A. O'Hara, C. M. Wilmot, J. E. Hutchins, P. J. Hoopes, and T. Hasan, " Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor.," Radiat. Res. 160, 452-459 (2003).
35. T. C. Zhu, J. C. Finlay, and S. M. Hahn, " Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.," J. Photochem. Photobiol., B 79, 231-241 (2005).
36. L. Lilge, K. Molpus, T. Hasan, and B. C. Wilson, " Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.," Photochem. Photobiol. 68, 281-288 (1998).